Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$0.00
12.50%
Nasdaq, Sep 16, 01:12 pm EDT. Market open.
ISIN
US0070251097
Symbol
ADTX

Aditx Therapeutics Inc Stock price

$0.01
+0.00 143.48% 1M
-43.73 99.99% 6M
-180.25 100.00% YTD
-24,212.73 100.00% 1Y
-4,764,441,599.99 100.00% 3Y
-785,937,599,999.99 100.00% 5Y
-2,470,089,599,999.99 100.00% 10Y
-2,470,089,599,999.99 100.00% 20Y
Nasdaq, Closing price Tue, Sep 15 2026
-0.00 13.85%
ISIN
US0070251097
Symbol
ADTX
Industry

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,143 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.6m
Enterprise Value
$8.6m
Net debt
$3.0m
Cash
$270.0k
Shares outstanding
40.0k
Valuation (TTM | estimate)
P/E
0.0
P/S
558.9 | -
EV/Sales
862.9 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
34.0%
Return on Equity
-768.3%
ROCE
-3,229.5%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$10.0k | -
EBITDA
$-18.2m
EBIT
$-18.4m
Net Income
$-53.3m
Free Cash Flow
$-18.6m
Growth (TTM | estimate)
Revenue
-83.3% | -
EBITDA
15.1%
EBIT
16.1%
Net Income
-70.3%
Free Cash Flow
17.5%
Margin
Gross
20.3%
EBITDA
-126,967.8%
EBIT
-128,730.1%
Net
-372,999.3%
Free Cash Flow
-129,914.7%
More
EPS
$-2,644.5
FCF per Share
$-464.4
Short interest
34.5%
Employees
26
Rev per Employee
$0.0

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Aditx Therapeutics Inc

Mar '26
+/-
%
0.01 0.01
83% 83%
100%
- Direct Costs 0.01 0.01
98% 98%
100%
- -
-
-
- Selling and Administrative Expenses 15 15
12% 12%
153,000%
- Research and Development Expense 3.03 3.03
23% 23%
30,300%
-18 -18
15% 15%
-181,600%
- Depreciation and Amortization 0.25 0.25
54% 54%
2,500%
EBIT (Operating Income) EBIT -18 -18
16% 16%
-184,084%
Net Profit -53 -53
70% 70%
-533,400%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
3 months ago
MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transacti...
Neutral
Business Wire
3 months ago
GOLDEN, Colo.--(BUSINESS WIRE)--Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”) a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite's CLIA-certified Reverse Phase Protein Array (“RPPA”) platform with structured clinical outcomes tracking to evaluate the real-w...
Neutral
Business Wire
4 months ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncolog...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Mr. Albanna
Employees 26
Founded 2017
Website aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today